A 42-year-old woman from Mumbai with a history of recurrent UTIs is admitted with sepsis secondary to a catheter-associated urinary tract infection. Blood and urine cultures grow Klebsiella pneumoniae. Antibiotic susceptibility testing shows resistance to fluoroquinolones, ceftazidime, and cefotaxime, but resistance to meropenem as well. Phenotypic testing suggests carbapenem resistance. PCR confirms the presence of a bla-NDM-1 gene (New Delhi metallo-β-lactamase). The patient is currently on no antibiotics and has a serum creatinine of 1.8 mg/dL. What is the most appropriate next step in management?

Explanation

## Clinical Context This patient has **carbapenem-resistant Enterobacteriaceae (CRE)** producing a metallo-β-lactamase (NDM-1). This is a pan-resistant organism with extremely limited treatment options. The presence of bla-NDM-1 confirms true carbapenem resistance, not ESBL. ## Carbapenem Resistance Mechanisms: ESBL vs. MBL | Feature | ESBL | Metallo-β-lactamase (NDM-1, VIM, IMP) | |---------|------|----------------------------------------| | Substrate | 3rd/4th gen cephalosporins, aztreonam | **Carbapenems + cephalosporins** | | Carbapenem susceptibility | **Susceptible** | **Resistant** | | Mechanism | Serine active site | **Zinc-dependent metalloenzyme** | | Inhibitor | Clavulanic acid, tazobactam | **Not inhibited by β-lactamase inhibitors** | | Treatment | Carbapenems (1st line) | Colistin, tigecycline, fosfomycin | **Key Point:** Metallo-β-lactamases (MBLs) are zinc-dependent enzymes that hydrolyze carbapenems. Unlike ESBLs, they are NOT inhibited by conventional β-lactamase inhibitors (clavulanic acid, tazobactam, sulbactam). NDM-1 is the most common MBL globally, first identified in New Delhi. ## Why Colistin Is the Next Step **High-Yield:** Colistin (polymyxin E) is a last-resort antibiotic for CRE/NDM-1 infections because: 1. It remains active against most MBL-producing organisms 2. It acts via membrane disruption (not β-lactam hydrolysis), bypassing resistance mechanisms 3. It is bactericidal at high concentrations 4. Alternatives (tigecycline, fosfomycin) have lower bactericidal activity and higher failure rates in sepsis **Clinical Pearl:** Colistin dosing in renal impairment requires adjustment. With serum creatinine 1.8 mg/dL (estimated CrCl ~30–40 mL/min), the patient needs dose reduction. Standard loading dose is 9 million units IV, then maintenance 4.5 million units IV 8-hourly (or 3 million units 12-hourly if CrCl <10 mL/min). Renal function monitoring is essential. ## Management Algorithm for CRE/NDM-1 ```mermaid flowchart TD A[CRE/NDM-1 infection confirmed]:::outcome A --> B{Clinical severity?}:::decision B -->|Sepsis/Bacteremia| C[Colistin IV ± tigecycline]:::action B -->|Uncomplicated UTI| D[Fosfomycin or tigecycline]:::action C --> E[Blood cultures before therapy]:::action E --> F[Source control: remove catheter if possible]:::action F --> G[Monitor renal function closely]:::action G --> H[Clinical response at 48-72 hours]:::outcome ``` **Warning:** Do NOT use carbapenems in confirmed MBL-producing organisms—they will fail. Ertapenem is also a carbapenem and will not work. ## Why Repeat Blood Cultures? **Key Point:** Repeat blood cultures after antibiotic initiation help confirm source control and guide duration of therapy. In catheter-associated infections, catheter removal is mandatory for cure. [cite:Harrison 21e Ch 297; Mandell, Douglas & Bennett 9e Ch 220]